Sander Bins

1.8k citations

59 papers · 1.2k · h-index 17

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Drug Transport and Resistance Mechanisms
- Lung Cancer Research Studies
- CAR-T cell therapy research
Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism

Papers in

Oncology 33
- Cancer Immunotherapy and Biomarkers 18
- Pancreatic and Hepatic Oncology Research 8
- Colorectal Cancer Treatments and Studies 7
- Drug Transport and Resistance Mechanisms 6
- CAR-T cell therapy research 4
Pulmonary and Respiratory Medicine 15
- Prostate Cancer Treatment and Research 5
- Lung Cancer Treatments and Mutations 4

Co-authors: Ron H.J. Mathijssen (53 shared papers)Ron H. N. van Schaik (14 shared papers)Femke M. de Man (5 shared papers)Andrew K.L. Goey (2 shared papers)Esther Oomen‐de Hoop (26 shared papers)Stijn L.W. Koolen (23 shared papers)Joachim G.J.V. Aerts (14 shared papers)Astrid A.M. van der Veldt (16 shared papers)
Journals: Annals of Oncology (9 papers)Clinical Pharmacokinetics (5 papers)European Journal of Cancer (3 papers)Journal of Clinical Oncology (3 papers)Clinical Cancer Research (3 papers)
Partner nations: Netherlands United States Sweden

In The Last Decade

Sander Bins

55 papers receiving 1.2k citations

Peers

Countries citing papers authored by Sander Bins

Since Specialization

Citations

This map shows the geographic impact of Sander Bins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander Bins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander Bins more than expected).

Fields of papers citing papers by Sander Bins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander Bins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander Bins. The network helps show where Sander Bins may publish in the future.

Co-authors

The 25 scholars most cited alongside Sander Bins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sander Bins Line = papers co-authored together Sander Bins links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics Clinical Pharmacokinetics ·Femke M. de Man, Andrew K.L. Goey, Ron H. N. van Schaik, Ron H.J. Mathijssen, Sander Bins	2018	305
2	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients Thyroid ·Edwin A. Basak, Jan W.M. van der Meer, Daan P. Hurkmans, Marco W.J. Schreurs, Esther Oomen‐de Hoop, Astrid A.M. van der Veldt, Sander Bins, Arjen Joosse, Stijn L.W. Koolen, Reno Debets, Robin P. Peeters, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Marco Medici	2020	70
3	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans, Edwin A. Basak, Tanja C. van Dijk, Darlene Mercieca, Marco W.J. Schreurs, Annemarie Wijkhuijs, Sander Bins, Esther Oomen‐de Hoop, Reno Debets, Markus Joerger, Arlette E. Odink, Astrid A.M. van der Veldt, Cor H. van der Leest, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen	2019	70
4	Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients Clinical Cancer Research ·Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen, Martijn P. Lolkema, Leni van Doorn, Jan H.M. Schellens, Jos H. Beijnen, Marlies H.G. Langenberg, Alwin D. R. Huitema, Neeltje Steeghs	2016	63
5	Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer European Journal of Cancer ·Edwin A. Basak, Stijn L.W. Koolen, Daan P. Hurkmans, Marco W.J. Schreurs, Sander Bins, Esther Oomen‐de Hoop, Annemarie Wijkhuijs, Ilse den Besten, Stefan Sleijfer, Reno Debets, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen	2019	55
6	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients British Journal of Cancer ·Sander Bins, Edwin A. Basak, Samira El Bouazzaoui, Stijn L.W. Koolen, Esther Oomen‐de Hoop, Cor H. van der Leest, Astrid A.M. van der Veldt, Stefan Sleijfer, Reno Debets, Ron H. N. van Schaik, Joachim G.J.V. Aerts, Ron H.J. Mathijssen	2018	54
7	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Esther Oomen‐de Hoop, Cor H. van der Leest, Samira El Bouazzaoui, Sander Bins, Stijn L.W. Koolen, Stefan Sleijfer, Astrid A.M. van der Veldt, Reno Debets, Ron H. N. van Schaik, Joachim G.J.V. Aerts, Ron H.J. Mathijssen	2020	53
8	CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation? Frontiers in Genetics ·Tessa A. M. Mulder, Ruben A.G. van Eerden, Mirjam de With, Laure Elens, Dennis A. Hesselink, Maja Matić, Sander Bins, Ron H.J. Mathijssen, Ron H. N. van Schaik	2021	50
9	CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab Journal for ImmunoTherapy of Cancer ·André Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcıoğlu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, C. B. H. W. Lamers, Sander Bins, Stijn L.W. Koolen, Astrid A.M. van der Veldt, Stefan Sleijfer, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Reno Debets	2019	44
10	Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients Clinical Pharmacokinetics ·(unknown), Nielka van Erp, Sander Bins, Ron H.J. Mathijssen, Jan H.M. Schellens, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema	2016	41
11	Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn beta2-agonists L. A. Laitinen, Ian Naya, Sander Bins, Autumn N. Harris	1997	27
12	Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies Drugs ·Niels A.D. Guchelaar, Bo Jan Noordman, Stijn L.W. Koolen, Bianca Mostert, Eva V. E. Madsen, Jacobus W. A. Burger, Alexandra R. M. Brandt‐Kerkhof, Geert-Jan Creemers, Ignace H. J. T. de Hingh, Misha Luyer, Sander Bins, Esther van Meerten, Sjoerd M. Lagarde, Cornelis Verhoef, Bas P. L. Wijnhoven, Ron H.J. Mathijssen	2023	26
13	Polymorphisms in SLCO1B1 and UGT1A1 are Associated with Sorafenib-Induced Toxicity Pharmacogenomics ·Sander Bins, Anne Lenting, Samira El Bouazzaoui, Leni van Doorn, Esther Oomen‐de Hoop, Ferry A.L.M. Eskens, Ron HN van Schaik, Ron H.J. Mathijssen	2016	26
14	Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide Clinical and Translational Science ·Sander Bins, Leni van Doorn, Mitch A. Phelps, AA Gibson, Shuiying Hu, L Li, A Vasilyeva, Guanting Du, Paul Hamberg, F. Eskens, Peter de Bruijn, Alex Sparreboom, Ron H.J. Mathijssen, Sharyn D. Baker	2017	25
15	Conventional Dosing of Anticancer Agents: Precisely Wrong or Just Inaccurate? Clinical Pharmacology & Therapeutics ·Sander Bins, Mark J. Ratain, Ron H.J. Mathijssen	2014	24
16	Impact of CYP3A422 on Pazopanib Pharmacokinetics in Cancer Patients Clinical Pharmacokinetics* ·Sander Bins, Alwin D. R. Huitema, Pim Laven, Samira El Bouazzaoui, Huixin Yu, Nielka van Erp, Carla van Herpen, Paul Hamberg, Hans Gelderblom, Neeltje Steeghs, Stefan Sleijfer, Ron H. N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen	2018	24
17	Development and Clinical Validation of an LC–MS/MS Method for The Quantification of Pazopanib in DBS Bioanalysis ·Remy B. Verheijen, Sander Bins, Bas Thijssen, Hilde Rosing, Lianda Nan, Jan H.M. Schellens, Ron H.J. Mathijssen, Martijn P. Lolkema, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema	2015	17
18	Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma The Journal of Clinical Endocrinology & Metabolism ·Carolien Beukhof, Leni van Doorn, Theo J. Visser, Sander Bins, W. Edward Visser, Ramona van Heerebeek, Folkert J. van Kemenade, Yolanda B. de Rijke, Wouter W. de Herder, Layal Chaker, Ron H.J. Mathijssen, Robin P. Peeters	2017	16
19	The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies Annals of Oncology ·G.A. Cirkel, Fleur Weeber, Sander Bins, Christa G.M. Gadellaa-van Hooijdonk, Erik van Werkhoven, Stefan M. Willems, Marijn van Stralen, Wouter B. Veldhuis, Inge Ubink, Neeltje Steeghs, Maja J. De Jonge, Marlies H.G. Langenberg, Jan H.M. Schellens, Stefan Sleijfer, Martijn P. Lolkema, Emile E. Voest	2016	15
20	Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD Biomedicine & Pharmacotherapy ·Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A. M. Mulder, Esther Oomen‐de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H. N. van Schaik, Sander Bins	2023	14

About Sander Bins

Sander Bins is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 59 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (18 papers), Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Prostate Cancer Treatment and Research (5 papers), CAR-T cell therapy research (4 papers), Cancer therapeutics and mechanisms (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Oncology (565 citations), Pharmacology (92 citations), Pulmonary and Respiratory Medicine (244 citations), Cancer Research (88 citations) and Immunology (127 citations). Sander Bins has collaborated with scholars based in Netherlands, United States and Sweden. Frequent co-authors include Ron H.J. Mathijssen, Ron H. N. van Schaik, Femke M. de Man, Andrew K.L. Goey, Esther Oomen‐de Hoop, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Astrid A.M. van der Veldt, Edwin A. Basak and Reno Debets. Their work appears in journals such as Annals of Oncology, Clinical Pharmacokinetics, European Journal of Cancer, Journal of Clinical Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Sander Bins

Impact in

Papers in i

In The Last Decade

Sander Bins

Peers

Countries citing papers authored by Sander Bins

Fields of papers citing papers by Sander Bins

All Works

About Sander Bins

Explore authors with similar magnitude of impact

Papers in